Pdt Partners, LLC Zynerba Pharmaceuticals, Inc. Transaction History

Pdt Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$3.72 - $5.35 $565,276 - $812,964	-151,956 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.83 - $5.98 $581,991 - $908,696	151,956 New	151,956 $804,000
Q1 2021 May 17, 2021	SELL	$3.33 - $8.76 $59,696 - $157,040	-17,927 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$3.27 - $4.64 $58,621 - $83,181	17,927 New	17,927 $59,000
Q3 2020 Nov 16, 2020	SELL	$3.23 - $4.3 $63,605 - $84,675	-19,692 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$3.31 - $6.54 $65,180 - $128,785	19,692 New	19,692 $66,000
Q2 2019 Aug 14, 2019	SELL	$5.4 - $15.5 $474,120 - $1.36 Million	-87,800 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$3.6 - $6.22 $123,840 - $213,968	34,400 Added 64.42%	87,800 $476,000
Q4 2018 Feb 14, 2019	BUY	$2.89 - $7.91 $154,326 - $422,394	53,400 New	53,400 $159,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.